News
11d
inews.co.uk on MSNWeight loss jabs to be given to 3,000 people in trial to get them back into workWeight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper ...
A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain ...
HealthDay News — For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction, according to a study ...
Companies are helping employees work smarter by deploying cloud-based collaboration tools, AI-powered workforce management platforms and secure mobile networks. IT modernization is at the core of ...
Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss ...
The American College of Cardiology has issued new guidelines recommending weight management medications as first-line treatments for eligible patients. This contrasts with prior guidelines that ...
Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to access life-changing weight loss medications.
Pennsylvania is evolving, and our workforce development system needs to adapt to this change. For years, there have been flashing red lights on Pennsylvania’s demographic dashboard. Our ...
Biotech 4DMT lays off 25% of workforce while accelerating phase 3 eye gene therapy timeline By James Waldron Jul 3, 2025 4:52am 4D Molecular Therapeutics Cell & Gene Therapy layoffs wet AMD ...
It’s no secret that America’s shipbuilding workforce is in crisis. The nation is struggling to retain a sufficient workforce to meet existing requirements. It’s also no secret that China is outpacing ...
Fresh concerns have emerged about the platelet studies underpinning the FDA approval of ticagrelor, AstraZeneca's multibillion-dollar heart drug. A new BMJ investigation reveals data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results